Home › Breast Cancer › Georgia
Breast Cancer clinical trials in Georgia
53 studies for Breast Cancer are looking for participants at sites in Georgia.
Cities in Georgia
- Atlanta41 studies
- Savannah11 studies
- Athens5 studies
- South Fulton5 studies
- Augusta5 studies
- Johns Creek4 studies
- Sandy Springs3 studies
- Gainesville3 studies
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Emory University Hospital, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05646862The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Emory University Winship Cancer Institute, Atlanta
- Liberty County Cancer Care, Hinesville
- Pembroke Medical Oncology & St Joseph's/Candler Oncology Infusion Suite, Pembroke
- and 2 more
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Sep 25, 2026 · NCT06377852A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- City of Hope Cancer Center - Atlanta ( Site 0102), Newnan
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0032), Thomasville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312176Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Marietta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07085767A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Piedmont Columbus Regional - John B. Amos Cancer Center, Columbus
- Central Georgia Cancer Care, Macon
- City of Hope National Medical Center, Atlanta Cancer Center, Newnan
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Winship Cancer Institute, Atlanta
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 22, 2026 · NCT07287098A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Emory University School of Medicine - Winship Cancer Institute, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07114601A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- University Cancer & Blood Center, LLC, Athens
- Winship Cancer Institute of Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06827236A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- University Blood & Cancer Center, LLC, Athens
- Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06492616Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Georgia Cancer Center at Augusta University, Augusta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- University Cancer & Blood Center, LLC, Athens
- Summit Cancer Care, Savannah
RecruitingPhase 1
Ages 18 to 55 · Women · Updated Sep 9, 2026 · NCT07310420A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
- Emory University (Data Collection Only), Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05570253A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Marietta
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Sep 8, 2026 · NCT07647328A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Winship Cancer Institute of Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT07100106A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06400472A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Northwest Georgia Oncology Centers PC - Marietta, Marietta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06790693Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Atlanta Cancer Care - Northside Hospital, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06982521Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Emory University, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT05846789Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phoebe Putney Memorial Hospital, Albany
- University Cancer and Blood Center LLC, Athens
- Grady Health System, Atlanta
- and 16 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Sep 2, 2026 · NCT05879926Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Northeast Georgia Medical Center Braselton, Braselton
- Atlanta VA Medical Center, Decatur
- Northeast Georgia Medical Center-Gainesville, Gainesville
- and 3 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Winship Cancer Institute of Emory University, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06072612Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Emory University - Winship Cancer Institute, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06582017A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- Augusta University, Augusta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06764940Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya
- Emory University Hospital/Winship Cancer Institute, Atlanta
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764796FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
- Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT05304962Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
- Winship Cancer Institute at Emory University, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06263543A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Northside Hospital, Atlanta
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06926868Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- City of Hope - Cancer Center Atlanta, Newnan
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Aug 6, 2026 · NCT05232916Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Augusta University Georgia Cancer Center, Augusta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- and 3 more
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Aug 4, 2026 · NCT06748222Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07288359A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Winship Cancer Institute, Emory University, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 27, 2026 · NCT06369285Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
- Emory Proton Therapy Center, Atlanta
RecruitingPhase 3
Ages 19 and older · Women · Updated Jul 10, 2026 · NCT05856773First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- GSK Investigational Site, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT04641247Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Emory University School of Medicine, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT05696626Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
- Emory University Hospital/Winship Cancer Institute, Atlanta
RecruitingHealthy volunteers welcome
Ages 25 and older · Women · Updated May 26, 2026 · NCT06760507Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
- Emory University/Winship Cancer Institute, Atlanta
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · Women · Updated May 7, 2026 · NCT05877859From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.